BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10492627)

  • 1. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).
    Songun I; Keizer HJ; Hermans J; Klementschitsch P; de Vries JE; Wils JA; van der Bijl J; van Krieken JH; van de Velde CJ
    Eur J Cancer; 1999 Apr; 35(4):558-62. PubMed ID: 10492627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
    Hartgrink HH; van de Velde CJ; Putter H; Songun I; Tesselaar ME; Kranenbarg EK; de Vries JE; Wils JA; van der Bijl J; van Krieken JH;
    Eur J Surg Oncol; 2004 Aug; 30(6):643-9. PubMed ID: 15256239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
    Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
    J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
    Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
    J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
    Kelsen D; Atiq OT; Saltz L; Niedzwiecki D; Ginn D; Chapman D; Heelan R; Lightdale C; Vinciguerra V; Brennan M
    J Clin Oncol; 1992 Apr; 10(4):541-8. PubMed ID: 1548519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
    Cocconi G; Carlini P; Gamboni A; Gasperoni S; RodinĂ² C; Zironi S; Bisagni G; Porrozzi S; Cognetti F; Di Costanzo F; Canaletti R; Ruggeri EM; Camisa R; Pucci F;
    Ann Oncol; 2003 Aug; 14(8):1258-63. PubMed ID: 12881389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
    Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
    Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
    Webb A; Cunningham D; Scarffe JH; Harper P; Norman A; Joffe JK; Hughes M; Mansi J; Findlay M; Hill A; Oates J; Nicolson M; Hickish T; O'Brien M; Iveson T; Watson M; Underhill C; Wardley A; Meehan M
    J Clin Oncol; 1997 Jan; 15(1):261-7. PubMed ID: 8996151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
    Nitti D; Wils J; Dos Santos JG; Fountzilas G; Conte PF; Sava C; Tres A; Coombes RC; Crivellari D; Marchet A; Sanchez E; Bliss JM; Homewood J; Couvreur ML; Hall E; Baron B; Woods E; Emson M; Van Cutsem E; Lise M; ;
    Ann Oncol; 2006 Feb; 17(2):262-9. PubMed ID: 16293676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
    Bar Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
    J Chemother; 2002 Dec; 14(6):623-6. PubMed ID: 12583555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
    Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
    World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
    Waters JS; Norman A; Cunningham D; Scarffe JH; Webb A; Harper P; Joffe JK; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
    Br J Cancer; 1999 Apr; 80(1-2):269-72. PubMed ID: 10390007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
    Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
    J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
    Wils JA; Klein HO; Wagener DJ; Bleiberg H; Reis H; Korsten F; Conroy T; Fickers M; Leyvraz S; Buyse M
    J Clin Oncol; 1991 May; 9(5):827-31. PubMed ID: 2016625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
    Murad AM; Santiago FF; Petroianu A; Rocha PR; Rodrigues MA; Rausch M
    Cancer; 1993 Jul; 72(1):37-41. PubMed ID: 8508427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
    Crookes P; Leichman CG; Leichman L; Tan M; Laine L; Stain S; Baranda J; Casagrande Y; Groshen S; Silberman H
    Cancer; 1997 May; 79(9):1767-75. PubMed ID: 9128994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of advanced gastric cancer.
    Wils J
    Semin Oncol; 1996 Jun; 23(3):397-406. PubMed ID: 8658224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
    Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
    J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in the treatment of gastric carcinoma.
    Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.